About KALA BIO, Inc.
https://www.kalarx.comKala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
CEO
David Elliot Lazar
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-10-21 | Reverse | 1:50 |
| 2022-08-26 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:985.09K
Value:$591.75K
PICTET ASSET MANAGEMENT LTD
Shares:392.11K
Value:$235.54K
WOODLINE PARTNERS LP
Shares:247.47K
Value:$148.65K
Summary
Showing Top 3 of 38
About KALA BIO, Inc.
https://www.kalarx.comKala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.24M ▼ | $-7.56M ▲ | 0% | $-1.07 ▲ | $-6.47M ▲ |
| Q2-2025 | $0 | $11.03M ▲ | $-11.15M ▼ | 0% | $-1.71 ▼ | $-10.01M ▼ |
| Q1-2025 | $0 ▼ | $10.65M ▲ | $-8.95M ▼ | 0% ▲ | $-1.41 ▲ | $-7.79M ▼ |
| Q4-2024 | $254K ▲ | $9.39M ▼ | $-8.18M ▲ | -3.22K% ▼ | $-1.74 ▲ | $-6.71M ▲ |
| Q3-2024 | $0 | $9.57M | $-8.95M | 0% | $-1.93 | $-7.41M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $21.1M ▼ | $25.02M ▼ | $1.11M ▼ | $-8.66M ▼ |
| Q2-2025 | $31.94M ▼ | $36.05M ▼ | $39.26M ▼ | $-3.21M ▼ |
| Q1-2025 | $42.22M ▼ | $48.25M ▼ | $42.54M ▼ | $5.71M ▼ |
| Q4-2024 | $51.18M ▲ | $55.48M ▲ | $43.15M ▼ | $12.33M ▲ |
| Q3-2024 | $49.2M | $54.08M | $47.22M | $6.86M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.56M ▲ | $-10.88M ▼ | $1K ▲ | $30K ▲ | $-10.85M ▼ | $-10.86M ▼ |
| Q2-2025 | $-11.15M ▼ | $-7.73M ▲ | $-16K ▼ | $-2.53M ▼ | $-10.28M ▼ | $-7.73M ▲ |
| Q1-2025 | $-8.95M ▼ | $-8.82M ▼ | $0 ▲ | $-135K ▼ | $-8.96M ▼ | $-8.82M ▼ |
| Q4-2024 | $-8.18M ▲ | $-4.6M ▲ | $-69K ▲ | $6.65M ▲ | $1.98M ▲ | $-4.67M ▲ |
| Q3-2024 | $-8.95M | $-4.72M | $-90K | $-180K | $-5M | $-4.68M |
CEO
David Elliot Lazar
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-10-21 | Reverse | 1:50 |
| 2022-08-26 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:985.09K
Value:$591.75K
PICTET ASSET MANAGEMENT LTD
Shares:392.11K
Value:$235.54K
WOODLINE PARTNERS LP
Shares:247.47K
Value:$148.65K
Summary
Showing Top 3 of 38